Avatrombopag is a medication approved by the United States Food and Drug Administration (USFDA) and the European Medicine Agency (EMA). The drug acts as a thrombopoietin receptor agonist, and it was indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are to undergo a planned medical or dental procedure.
.
Avatrombopag is a non-chiral compound that contains 6 rings in the molecule, 5 of which are heterocycles. The 4 six-membered rings are cyclohexane, piperazine, pyridine, and piperidine; the 2 five-membered rings consist of thiophene and thiazole. The rings are directly connected to one another or through an amide bond. The key steps for the synthesis of Avatrombopag involve a selective nucleophilic aromatic substitution reaction and an amide bond formation reaction.
.
References: J. Med. Chem. 2020, 63, 10652. doi.org/10.102...
23 сен 2024
